Literature DB >> 11564652

Effects of adenosine receptor agonists and antagonists in a genetic animal model of primary paroxysmal dystonia.

A Richter1, M Hamann.   

Abstract

1. Recent studies have shown beneficial effects of an adenosine A(2A) receptor agonist in dt(sz) mutant hamsters, an animal model of paroxysmal dystonia, in which stress and consumption of coffee can precipitate dystonic attacks. This prompted us to examine the effects of adenosine receptor agonists and antagonists on severity of dystonia in dt(sz) hamsters in more detail. 2. The non-selective adenosine A(1)/A(2A) receptor antagonists, caffeine (10 - 20 mg kg(-1) i.p.) and theophylline (10 - 30 mg kg(-1) s.c.), worsened the dystonia in dt(sz) hamsters. 3. Aggravation of dystonia was also caused by the selective adenosine A(1)/A(2A) antagonist CGS 15943 (9-chloro2-2-furyl)[1,2,4]triazolo[1,5-c]quinazolin-5-amine) at a dose of 30 mg kg(-1) i.p. and by the adenosine A(1) antagonist DPCPX (8-cyclopentyl-1,3-dipropylxanthine; 20 - 30 mg kg(-1) i.p.), while the A(2) antagonist DMPX (3,7-dimethyl-1-propargylxanthine; 2 - 4 mg kg(-1) i.p.) and the highly selective A(2A) antagonist ZM 241385 (4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol; 2 - 5 mg kg(-1) i.p.) failed to exert any effects on dystonia. 4. In contrast to the antagonists, both the adenosine A(1) receptor agonist CPA (N(6)-cyclopentyladenosine; 0.1 - 1.0 mg kg(-1) i.p.) and the A(2A) agonist CGS 21680 (2p-(2carboxyethylphen-ethylamino-5'-N-ethylcarboxamindoadenosine; 0.1 - 2.0 mg kg(-1) i.p.) exerted a striking improvement of dystonia. 5. These data suggest that the precipitating effects of methylxanthines are, at least in part, related to their adenosine receptor antagonistic action. 6. Although adenosine receptor agonists can be regarded as interesting candidates for the therapy of paroxysmal dystonia, adverse effects may limit the therapeutic potential of adenosine A(1) agonists, while beneficial effects of the adenosine A(2A) agonist CGS 21680 were already found at well tolerated doses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11564652      PMCID: PMC1572962          DOI: 10.1038/sj.bjp.0704268

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  34 in total

Review 1.  The dystonias.

Authors:  C D Marsden; N P Quinn
Journal:  BMJ       Date:  1990-01-20

2.  CGS 21680 exerts marked antidystonic effects in a genetic model of paroxysmal dyskinesia.

Authors:  A Richter; M Hamann; C Bartling
Journal:  Eur J Pharmacol       Date:  2000-09-22       Impact factor: 4.432

3.  Deficit of striatal parvalbumin-reactive GABAergic interneurons and decreased basal ganglia output in a genetic rodent model of idiopathic paroxysmal dystonia.

Authors:  M Gernert; M Hamann; M Bennay; W Löscher; A Richter
Journal:  J Neurosci       Date:  2000-09-15       Impact factor: 6.167

4.  Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys.

Authors:  T Kanda; M J Jackson; L A Smith; R K Pearce; J Nakamura; H Kase; Y Kuwana; P Jenner
Journal:  Ann Neurol       Date:  1998-04       Impact factor: 10.422

5.  Evidence for striatal dopaminergic overactivity in paroxysmal dystonia indicated by microinjections in a genetic rodent model.

Authors:  J H Rehders; W Löscher; A Richter
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

6.  Differential effect of stress on in vivo dopamine release in striatum, nucleus accumbens, and medial frontal cortex.

Authors:  E D Abercrombie; K A Keefe; D S DiFrischia; M J Zigmond
Journal:  J Neurochem       Date:  1989-05       Impact factor: 5.372

7.  Adenosine agonists can both inhibit and enhance in vivo striatal dopamine release.

Authors:  T Zetterström; M Fillenz
Journal:  Eur J Pharmacol       Date:  1990-05-03       Impact factor: 4.432

8.  Therapeutic aspects of kinesiogenic paroxysmal choreoathetosis and familial paroxysmal choreoathetosis of the Mount and Reback type.

Authors:  H Przuntek; P Monninger
Journal:  J Neurol       Date:  1983       Impact factor: 4.849

9.  Effects of pharmacological manipulation of GABAergic neurotransmission in a new mutant hamster model of paroxysmal dystonia.

Authors:  G Fredow; W Löscher
Journal:  Eur J Pharmacol       Date:  1991-01-10       Impact factor: 4.432

10.  The sz mutant hamster: a genetic model of epilepsy or of paroxysmal dystonia?

Authors:  W Löscher; J E Fisher; D Schmidt; G Fredow; D Hönack; W B Iturrian
Journal:  Mov Disord       Date:  1989       Impact factor: 10.338

View more
  4 in total

1.  Multiple adenosine receptor subtypes stimulate wound healing in human EA.hy926 endothelial cells.

Authors:  Zeinab Bonyanian; Matthew Walker; Eugene Du Toit; Roselyn B Rose'Meyer
Journal:  Purinergic Signal       Date:  2019-06-28       Impact factor: 3.765

Review 2.  The neurobiological basis for novel experimental therapeutics in dystonia.

Authors:  Anthony M Downs; Kaitlyn M Roman; Simone A Campbell; Antonio Pisani; Ellen J Hess; Paola Bonsi
Journal:  Neurobiol Dis       Date:  2019-07-04       Impact factor: 5.996

3.  Neuroprotection by adenosine in the brain: From A(1) receptor activation to A (2A) receptor blockade.

Authors:  Rodrigo A Cunha
Journal:  Purinergic Signal       Date:  2005-03-17       Impact factor: 3.765

4.  Multitarget Multiscale Simulation for Pharmacological Treatment of Dystonia in Motor Cortex.

Authors:  Samuel A Neymotin; Salvador Dura-Bernal; Peter Lakatos; Terence D Sanger; William W Lytton
Journal:  Front Pharmacol       Date:  2016-06-14       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.